GGrantIndex
Sort

78,016 grants matching breast cancer

Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapy

$441,967
Stephen Matthew Hatfield · Northeastern University · R01 · FY2024 · EB

Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer

$441,943
Debabrata Chakravarti · Northwestern University At Chicago · R01 · FY2017 · CA

Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer

$441,943
Debabrata Chakravarti · Northwestern University At Chicago · R01 · FY2016 · CA

Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer

$441,943
Debabrata Chakravarti · Northwestern University At Chicago · R01 · FY2015 · CA

VIRTUAL DIALOGUE METHOD FOR PATIENT EDUCATION

$441,897
Interactive Drama, Inc. · R44 · FY2002 · NR

Identifying the pro-metastatic mechanisms of neutrophil extracellular traps

$441,891
Mikala Egeblad · Johns Hopkins University · R01 · FY2024 · CA

Monitoring neoadjuvant chemotherapy of breast cancer using 3D subharmonic aided pressure estimation

$441,876
Kibo Nam · Thomas Jefferson University · R37 · FY2024 · CA

NETS in thrombosis and inflammatory responses

$441,875
Denisa D Wagner · Boston Children'S Hospital · R01 · FY2015 · HL

Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer

$441,858
Xiaoming He · Univ Of Maryland, College Park · R01 · FY2023 · CA

BIODEGRADABLE NANOPARTICLE FORMULATED TAXOL FOR TARGETED THERAPY OF HEAD AND NECK

$441,856
Shuming Nie · Emory University · P50 · FY2009 · CA

Project 2: Targeted Therapies for Malignant Peripheral Nerve Sheath Tumors

$441,855
Stephen X Skapek · Indiana University Indianapolis · U54 · FY2017 · CA

Enhancing Tumor Antigen Presentation with Complement Targeted Nanoparticles

$441,796
Max Peter Kullberg · University Of Alaska Anchorage · R15 · FY2022 · CA

Development and validation of clinical prediction models for the use and interpretation of multigene hereditary cancer risk assessment

$441,779
Sapna Syngal · Dana-Farber Cancer Inst · R01 · FY2019 · CA

LOW FAT DIET AND BREAST CANCER RECURRENCE--OUTCOME TRIAL

$441,722
La Biomed Res Inst/ Harbor Ucla Med Ctr · R01 · FY2004 · CA

Targeting ER+ Breast Cancer Through Induced Viral Mimicry

$441,716
Charles H Spruck · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2022 · CA

Role of StAR-related lipid transfer protein 10 in alcohol-induced breast cancer progression

$441,680
Maria Lauda Tomasi · Cedars-Sinai Medical Center · R01 · FY2024 · AA

Clinical Protocol and Data Management

$441,633
Dennis J Slamon · University Of California Los Angeles · P30 · FY2020 · CA

Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer

$441,579
Xiaoming He · Univ Of Maryland, College Park · R01 · FY2022 · CA

Improving the Estimation and Communication of Ovarian Cancer Risk Among BRCA1/2 C

$441,569
Mary Beryl Daly · Fox Chase Cancer Center · P50 · FY2010 · CA

RESEARCH CORE

$441,565
George Stancel · University Of Tx Md Anderson Can Ctr · P60 · FY2008 · MD

Targeting vulnerabilities in copper metabolism in the development of cancer therapies

$441,538
Michael J Petris · University Of Missouri-Columbia · R01 · FY2024 · CA

Role of TbRIII in Regulating Motility and Invasion

$441,531
Gerard C Blobe · Duke University · R01 · FY2010 · CA

Cancer Control Research Training Curriculum

$441,513
Gary R Morrow · University Of Rochester · R25 · FY2010 · CA

Regulation of tumor-infiltrating T cells by macrophages

$441,506
Xiaopei Huang · Ohio State University · R01 · FY2025 · CA

Glycomics Laboratory for the Early Detection of Epithelial Ovarian Cancer

$441,461
Karen L. Abbott · Univ Of Arkansas For Med Scis · U01 · FY2015 · CA